CClinicalTrials.gg
RecruitingNCT07428057Updated Sep 22, 2026

Postoperative Hypocalcemia After Thyroidectomy

An observational study in Thyroid Nodule, Thyroid Dysfunction and Hypocalcemia, sponsored by Minia University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Minia University · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
600
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This retrospective cohort study investigates predictors of postoperative hypocalcemia following thyroidectomy procedures at Minia University Hospital over a 10-year period (2014-2024). Postthyroidectomy hypocalcemia is one of the most common complications of thyroid surgery, affecting 20-50% of patients. The study aims to identify demographic, clinical, laboratory, and surgical factors associated with the development of both transient and permanent hypocalcemia. Results will inform risk stratification, patient counseling, and perioperative management strategies.

Read the detailed description

Hypocalcemia is a frequent complication following thyroidectomy, resulting from inadvertent parathyroid gland injury, removal, or devascularization. While most cases resolve within 6 months (transient hypocalcemia),permanent hypocalcemia occurs in 1-3% of patients and requires lifelong calcium and vitamin D supplementation, significantly impacting quality of life.

This single-center retrospective study will systematically review medical records of all patients who underwent thyroidectomy (total, subtotal, or completion) at Minia University Hospital between January 1, 2014, andDecember 31, 2024. The primary objective is to identify independent predictors of postoperative hypocalcemia using multiple logistic regression analysis.

Data extraction will include:

Demographics: age, gender, BMI Clinical factors: indication for surgery, thyroid disease type, presence of Graves' disease, substernal extension Preoperative laboratory values: calcium, vitamin D, PTH, thyroid function tests Surgical details: extent of thyroidectomy, central/lateral lymph node dissection, surgeon experience,operative time, parathyroid gland identification and autotransplantation Postoperative data: calcium levels (24h, 48h, 1 week, 6 weeks, 3 months, 6 months), PTH levels,supplementation requirements Pathology: thyroid weight, presence of parathyroid tissue in specimen, thyroiditis, malignancy The study will employ robust statistical methods including univariate analysis to screen potential predictors and multiple logistic regression to identify independent risk factors. A clinical risk prediction score will be developed and internally validated using split-sample methodology. Subgroup analyses will examine differences between transient and permanent hypocalcemia and stratify results by extent of surgery and surgeon experience.

Target sample size of 500-600 patients was calculated using G*Power to ensure adequate statistical power(>80%) .

Findings will contribute to evidence-based perioperative protocols, improved patient selection for outpatient thyroidectomy, tailored monitoring strategies, and informed decision-making regarding prophylactic calcium supplementation.

02

Conditions studied

  • Thyroid Nodule
  • Thyroid Dysfunction
  • Hypocalcemia
  • Thyroid Cancer
  • Postoperative Complications

Keywords

  • Thyroidectomy
  • Postoperative hypocalcemia
  • Hypoparathyroidism
  • Parathyroid gland injury
  • Total thyroidectomy
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This retrospective cohort study will include adult patients (aged 18 years and older) who underwent a thyroidectomy procedure at Minia University Hospital, a tertiary care centre in Egypt, between January 1, 2014, and December 31, 2024. The target population consists of approximately 600 consecutive patients who meet the eligibility criteria. This includes patients with available medical records containing complete surgical and postoperative data, documented postoperative serum calcium levels, and a minimum of 6 months of follow-up or a documented outcome status. Patients will be excluded if they have preoperative hypocalcemia, pre-existing parathyroid disorders, chronic kidney disease (Stage 3 or higher), or other conditions that significantly affect calcium metabolism. The study population represents a consecutive sample of all patients meeting these criteria over the 10-year study period at this single academic center.

Inclusion criteria

  • Adult patients aged 18 years or older at time of surgery
  • Underwent thyroidectomy at Minia University Hospital
  • Availability of medical records with complete surgical and postoperative data
  • Documented serum calcium levels measured postoperatively
  • Minimum follow-up of 6 months postoperatively or documented outcome status

Exclusion criteria

Exclusion Criteria:

  • Age less than 18 years at time of surgery
  • Preoperative hypocalcemia (serum calcium \<8.0 mg/dL or ionized calcium \<1.0 mmol/L)
  • Pre-existing parathyroid disorders (primary hyperparathyroidism, hypoparathyroidism, secondary or tertiary hyperparathyroidism)
  • Chronic kidney disease Stage 3 or higher (estimated glomerular filtration rate \<60 mL/min/1.73m²)
  • Malabsorption syndromes affecting calcium metabolism (celiac disease, inflammatory bowel disease,short bowel syndrome)
  • Concurrent planned parathyroidectomy
  • History of neck irradiation
  • Chronic use of medications significantly affecting calcium metabolism (bisphosphonates, denosumab,cinacalcet, chronic corticosteroids)
  • Incomplete medical records lacking essential data including surgical details, postoperative calcium levels,or follow-up data
  • Patients lost to follow-up before 6-month endpoint without documented outcome status
04

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
600 participants (estimated)
Patient registry
No
05

What researchers measure

Primary outcomes

  1. Incidence of Postoperative Hypocalcemia

    Development of hypocalcemia defined as: Serum total calcium \<8.0 mg/dL (2.0 mmol/L) OR Ionized calcium \<1.0 mmol/L OR Symptomatic hypocalcemia (perioral numbness, paresthesias, carpopedal spasm, positive Chvostek's orTrousseau's sign) requiring calcium supplementation Measured at: 24 hours, 48 hours, 1 week, 6 weeks, 3 months, and 6 months postoperatively

    Time frame: Within 6 months post-surgery

Secondary outcomes

  1. Incidence of Transient Hypocalcemia

    Hypocalcemia that resolves within 6 months of surgery without need for continued calcium and/or vitamin D supplementation beyond 6-month follow-up

    Time frame: Up to 6 months post-surgery

  2. Incidence of Permanent Hypocalcemia

    Hypocalcemia requiring ongoing calcium and/or vitamin D supplementation persisting beyond 6months postoperatively, indicating permanent hypoparathyroidism

    Time frame: 6 months post-surgery

  3. Incidence of Symptomatic Hypocalcemia

    Clinical manifestations of hypocalcemia including: Neuromuscular irritability (perioral tingling, paresthesias) Tetany or carpopedal spasm Positive Chvostek's sign (facial nerve twitching) Positive Trousseau's sign (carpal spasm with blood pressure cuff inflation) Seizures (rare) Cardiac manifestations: prolonged QT interval, arrhythmias (rare)

    Time frame: Within 2 weeks post-surgery

  4. Hospital Length of Stay

    Duration of hospitalization in days following thyroidectomy, measured from date of surgery to date of hospital discharge

    Time frame: From surgery to discharge, typically 2-5 days

  5. Calcium and Vitamin D Supplementation Requirement

    Need for oral calcium supplementation (yes/no and total daily dose in mg) Need for vitamin D supplementation (yes/no and total daily dose in IU) Duration of supplementation (days/weeks) Need for intravenous calcium administration (yes/no)

    Time frame: Up to 6 months post-surgery

  6. Emergency Department Visits for Hypocalcemia

    Unplanned emergency department visits related to symptoms of hypocalcemia or complications of calcium/vitamin D therapy

    Time frame: Within 30 days post-discharge

  7. Hospital Readmission Related to Hypocalcemia

    Unplanned hospital readmission related to symptomatic hypocalcemia or its complications

    Time frame: Within 30 days post-discharge

  8. Postoperative Parathyroid Hormone (PTH) Level

    Serum intact parathyroid hormone level measured within 24 hours postoperatively (pg/mL), used as predictor of sustained hypocalcemia

    Time frame: 24 hours post-surgery

  9. Nadir Calcium Level

    Lowest serum calcium level (total or ionized) recorded during initial hospitalization or within first week postoperatively

    Time frame: Within 7 days post-surgery

  10. Time to Calcium Normalization

    Duration in days from surgery to sustained normalization of serum calcium levels without supplementation (for those who develop hypocalcemia)

    Time frame: Up to 6 months post-surgery

06

Study locations

1 of 1 sites recruiting
  • Minia University Hospital
    Minya, Minya Governorate 61519, Egypt
    Recruiting
07

References and documents

Publications

  • Edafe O, Antakia R, Laskar N, Uttley L, Balasubramanian SP. Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. Br J Surg. 2014 Mar;101(4):307-20. doi: 10.1002/bjs.9384. Epub 2014 Jan 9. PubMed 24402815 ↗
  • Thomusch O, Machens A, Sekulla C, Ukkat J, Brauckhoff M, Dralle H. The impact of surgical technique on postoperative hypoparathyroidism in bilateral thyroid surgery: a multivariate analysis of 5846 consecutive patients. Surgery. 2003 Feb;133(2):180-5. doi: 10.1067/msy.2003.61. PubMed 12605179 ↗
  • Lorente-Poch L, Sancho JJ, Ruiz S, Sitges-Serra A. Importance of in situ preservation of parathyroid glands during total thyroidectomy. Br J Surg. 2015 Mar;102(4):359-67. doi: 10.1002/bjs.9676. Epub 2015 Jan 20. PubMed 25605285 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT07428057
Lead sponsor
Minia University
Responsible party
Saleh Khairy Saleh MD (Lecturer, Minia University) — Principal investigator
First posted
Feb 23, 2026
Start date
Jan 1, 2014
Primary completion
Dec 1, 2026 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Sep 22, 2026

Study contacts

Saleh K Saleh, MD
Contact
salehkhairy@mu.edu.eg
01201765401 ext. +2
Saleh K Saleh, MD
principal investigator · Minia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion